New approaches to optimize treatment responses in chronic hepatitis B.

StephenW

Antivir Ther. 2010;15 Suppl 3:61-8.

New approaches to optimize treatment responses in chronic hepatitis B.

Brunetto MR, Lok AS.

Hepatology Unit, University Hospital of Pisa, Pisa, Italy.
[email protected]


Abstract
Substantial advances have been made in the treatment of chronic hepatitis
B in the past decade. Currently, there are seven approved agents including
two forms of interferon (conventional and pegylated), and five oral
nucleoside/nucleotide analogues (lamivudine, adefovir, entecavir,
telbivudine and tenofovir disoproxil fumarate). The availability of these
multiple treatment options has led to expansion of treatment indications.
However, the need for a long duration of treatment with some therapies,
the high costs of HBV medications, the side effects associated with some
treatments and the risks of drug resistance during long-term use of oral
antiviral medications necessitate the careful assessment of the
risk-benefit ratio prior to initiating treatment, and the evaluation of
better strategies to optimize response once treatment is initiated. In
this article, we review the current approaches to optimize treatment
response to nucleoside/nucleotide analogue- and interferon-based therapies
for chronic hepatitis B.

PMID: 21041905 [PubMed - in process]

Antivir。 2010年，15增刊3:61-8。

新的办法来优化治疗慢性乙型肝炎的响应

布鲁涅托议员，Lok AS。

肝病学组，比萨大学，比萨医院，意大利。
[email protected]


摘要
取得了实质性进展，在治疗慢性肝炎
乙方在过去的十年。目前，有七个批准剂包括
两种形式的干扰素（传统和聚乙二醇化），五口
核苷/（拉米夫定，阿德福韦，恩替卡韦核苷类似物，
替比夫定和替诺福韦disoproxil富马酸）。这些可用性
多种治疗方案，导致治疗的适应症扩大。
然而，与一些疗法的治疗时间长的需要，
乙型肝炎病毒药物的成本高，一边与一些相关影响
治疗及耐药性的风险在长期使用口服
抗病毒药物的必要认真评估
风险收益比前开始治疗，并评价
更好的策略，一旦治疗优化响应启动。在
这篇文章中，我们审查，以优化目前的治疗方法
针对核苷/核苷酸类似物和干扰素疗法
慢性乙型肝炎

结论：21041905 [PubMed的 - 过程]